Bcl-2 expression and triple negative profile in breast carcinoma

Medical Oncology

Volumn 28, Issue SUPPL. 1, 2011, Pages

  Kallel Bayoudh, Imen ^a   Hassen, Hanen Ben ^a   Khabir, Abdelmajid ^b   Boujelbene, Noureddine ^b   Daoud, Jamel ^b   Frikha, Mounir ^c   Sallemi Boudawara, Tahia ^b   Aifa, Sami ^a   Rebaï, Ahmed ^a  

^a CENTRE DE BIOTECHNOLOGIE DE SFAX   (Tunisia)

^b HABIB BOURGUIBA HOSPITAL   (Tunisia)

^c HEDI CHAKER HOSPITAL   (Tunisia)

Author keywords

BCL2 expression; Breast cancer; Prognosis; Triple negative profile

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN BCL 2;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR VOLUME;

EID: 84655175033     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-010-9694-x     Document Type: Article

References (46)

1. GM Callagy MJ Webber PDP Pharoah C Caldas 2008 Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer BMC Cancer 8 153
2. TJ [tmp] McDonnell SJ Korsmeyer 1991 Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t (14; 18) Nature 349 254 256 (Pubitemid 21912060)
3. TJ [tmp] McDonnell P Troncoso SM Brisbay C Logothetis LW Chung JT Hsieh SM Tu ML Campbell 1992 Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer Cancer Res 52 6940 6944 (Pubitemid 23006303)
4. JA Pietenpol N Papadopoulos S Markowitz JK Willson KW Kinzler B Vogelstein 1994 Paradoxical inhibition of solid tumor cell growth by bcl2 Cancer Res 54 3714 3717 (Pubitemid 24241185)
5. HJ Van Slooten PC Clahsen JH van Dierendonck C Duval C Pallud AM Mandard A Delobelle-Deroide CJ van de Velde MJ van de Vijver 1996 Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to onecourse of perioperative chemotherapy Br J Cancer 74 78 85 (Pubitemid 26231982)
6. A Linjawi M Kontogiannea F Halwani M Edwardes S Meterissian 2004 Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer J Am Coll Surg 198 83 90 (Pubitemid 38201092)
7. KH Lee SA Im DY Oh SH Lee EK Chie W Han DW Kim TY Kim IA Park DY Noh DS Heo SW Ha YJ Bang 2007 Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy BMC Cancer 7 63
8. Y Nadler RL Camp JM Giltnane C Moeder DL Rimm HM Kluger Y Kluger 2008 Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer Breast Cancer Res 10 R35
9. V Bhargava DL Kell M Van de Rijn RA Warnke 1994 Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity Am J Pathol 145 535 540 (Pubitemid 24285961)
10. N Bilalovic S Vranic S Hasanagic H Basic A Tatarevic S Beslija 2004 The Bcl-2 protein: a prognostic indicator strongly related to ER and PR in breast cancer Bosn J Basic Med Sci 4 5 12
11. Y Yarden MX Sliwkowski 2001 Untangling the ErbB signalling network Nat Rev Mol Cell Biol 2 127 137 (Pubitemid 33674041)
12. R [tmp] McKean-Cowdin LN Kolonel MF Press MC Pike BE Henderson 2001 Germ-line HER-2 variant and breast cancer risk by stage of disease Cancer Res 61 8393 8394 (Pubitemid 33131112)
13. S Tommasi V Fedele A Crapolicchio A Bellizzi A Paradiso SJ Reshkin 2003 ErbB2 and the antimetastatic nm23/NDP kinase in regulating serum induced breast cancer invasion Int J Mol Med 12 131 134
14. D Picard G Bunone JW Liu O Donzw 1997 Steroid independent activation of steroid receptors in mammalian and yeast cells and in breast cancer Biochem Soc Trans 25 597 602 (Pubitemid 27260879)
15. WL [tmp] McGuire 1978 Hormone receptors: their role in predicting prognosis and response to endocrine therapy Semin Oncol 5 428 433 (Pubitemid 9097045)
16. R Clarke T Skaar K Baumann F Leonessa M James J Lippman EW Thompson C Freter N Brunner 1994 Hormonol carcinogenesis in breast cancer: cellular and molecular studies of malignant progression Breast Cancer Res Treat 31 237 248 (Pubitemid 24323465)
17. RI Nicholson RA [tmp] McClelland JM Gee DL Manning P Cannon JF Robertson IO Ellis RW Blamey 1994 Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy Breast Cancer Res Treat 29 117 125 (Pubitemid 24104843)
18. B Kreike M van Kouwenhove H Horlings B Weigelt H Peterse H Bartelink MJ van de Vijver 2007 Gene expression profiling and histopathological characterization of triple negative/basal-like breast carcinomas Breast Cancer Res R9 65
19. CM Perou T Sorlie MB Eisen M van de Rijn SS Jeffrey CA Rees JR Pollack DT Ross H Johnsen LA Akslen O Fluge A Pergamenschikov C Williams SX Zhu PE Lønning AL Børresen-Dale PO Brown D Botstein 2000 Molecular portraits of human breast tumors Nature 406 747 752
20. S Cleator W Heller RC Coombes 2007 Triple-negative breast cancer: therapeutic options Lancet Oncol 8 235 244 (Pubitemid 46291713)
21. VR Grann AB Troxel NJ Zojwalla JS Jacobson D Hershman AI Neugut 2005 Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma Cancer 103 2241 2251 (Pubitemid 40686567)
22. HJ Bloom WW Richardson 1957 Histological grading and prognosis in breast cancer: a study of 1,409 cases of which 359 have been followed for 15 years Br J Cancer 11 359 377
23. A Khabir A Ghorbel J Daoud M Frikha MM Drira A Laplanche P Busson R Jlidi 2003 Similar BCL-X but different BCL-2 levels in the two age groups of North African nasopharyngeal carcinomas Cancer Detect Prev 27 250 255 (Pubitemid 36990242)
24. H BenHassen F Masmoudi A Rebai 2009 Inference in signal transduction pathways with incomplete data: comparison between the EM algorithm and a new implicit algorithm J Comput Biol 16 1227 1240
25. L Bouchaala A Masmoudi A Rebai 2010 Improving algorithms for structure learning in Bayesian networks using a new implicit score Expert Syst Appl 37 5470 5475
26. Sivridis E, Stamos C, Fiska A, Nikolettos N, Koukourakis MI, Giatromanolaki A.c-erbB-2 and the "triple-state" in early breast carcinomas. Med Oncol 2009.
27. DM Hockenbery M Zutter W Hickey M Nahm SJ Korsmeyer 1991 BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death Proc Natl Acad Sci 88 6961 6965 (Pubitemid 21915069)
28. DT Chao SJ Korsmeyer 1998 BCL-2 family: regulators of cell death Annu Rev Immunol 16 395 419 (Pubitemid 28183370)
29. S Luna-Moré S Casquero A Pérez-Mellado F Rius B Weill I Gornemann 2000 Importance of estrogen receptors for the behavior of invasive micropapillary carcinoma of the breast. Review of 68 cases with follow-up of 54 Pathol Res Pract 196 35 39 (Pubitemid 30046524)
30. S Wang D Yang ME Lippman 2003 Targeting Bcl-2 and Bcl-XL with non peptidic small-molecule antagonists Semin Oncol 30 132 142
31. S Rehman J Crow PA Revell 2000 Bax protein expression in DCIS of the breast in relation to invasive ductal carcinoma and other molecular markers Pathol Oncol Res 6 256 263 (Pubitemid 32167618)
32. A Sierra X Castellsague A Escobedo B Lloveras M Garcia-Ramirez A Moreno A Fabra 2000 Bcl2 with loss of apoptosis allows accumulation of genetic alterations: a pathway to metastatic progression in human breast cancer Int J Cancer 89 142 147 (Pubitemid 30185922)
33. Y Fernandez B Gu A Martinez A Torregrosa A Sierra 2002 Inhibition of apoptosis in human breast cancer cells: role in tumor progression to the metastatic state Int J Cancer 101 317 326 (Pubitemid 34983186)
34. G Gasparini M Barbareschi C Doglioni PD Palma FA Mauri P Boracchi P Bevilacqua O Caffo L Morelli P Verderio F Pezzella AL Harris 1995 Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer Clin Cancer Res 1 189 198
35. S Tsutsui K Yasuda K Suzuki H Takeuchi T Nishizaki H Higashi Era Sf 2006 Bcl-2 protein expression is associated with p27 and p53 protein expressions and MIB-1 counts in breast cancer BMC Cancer 6 187
36. RM Elledge S Green L Howes GM Clark M Berardo DC Allred R Pugh D Ciocca P Radvin J O'sullivan S Rivkin S Martino CK Osborne 1997 bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study J Clin Oncol 15 1916 1922 (Pubitemid 27209521)
37. Q Yang T Sakurai X Jing H Utsunomiya L Shan Y Nakamura M Nakamura S Oura T Suzuma G Yoshimura T Umemura Y Kokawa K Nakudo 1999 Expression of Bcl2, but not Bax, correlates with estrogen receptor status and tumour proliferation in invasive breast carcinoma Pathol Int 49 775 780 (Pubitemid 29513291)
38. M Kyndi FB Sorensen H Knudsen J Alsner M Overgaard HM Nielsen J Overgaard 2008 Impact of BCL2 and p53 on postmastectomy radiotherapy response in high-risk breast cancer. A subgroup analysis of DBCG82 b&c Acta Oncol 47 608 617 (Pubitemid 351878461)
39. N Kroger KM Langosch S Riethdorf C Schmoor M Schumacher AR Zander T Loning 2006 Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients Clin Cancer Res 12 1 159 168 (Pubitemid 43166190)
40. Masmoudi Y, Chabchoub H, Hanafi S, Rebai A. A Mathematical Programming based Procedure for Breast Cancer Classification. J Math Model Algorithms. 2010; in press.
41. R Dent M Trudeau KI Pritchard WM Hanna HK Kahn CA Sawka LA Lickley E Rawlinson P Sun SA Narod 2007 Triple negative breast cancer: clinical features and patterns of recurrence Clin Cancer Res 13 4429 4434 (Pubitemid 47219710)
42. EA Rakha ME EL-Sayed AR Grenn AH Lee JF Robertson 2007 Ellis IO: prognostic markers in triple-negative breast cancer Cancer 109 25 32 (Pubitemid 46120191)
43. CA Livasy G Karaca R Nanda MS Tretiakova OI Olopade DT Moore CM Perou 2006 Phenotypic evaluation of the basal-like subtype of invasive breast carcinomas Mod Pathol 19 264 271 (Pubitemid 43117611)
44. LG Fulford DF Easton JS Reis-Filho A Sofronis CE Gillett SR Lakhani A Hanby 2006 Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast Histopathology 49 22 34 (Pubitemid 43972917)
45. J William Irvin Jr A Lisa 2008 Carey: what is triple-negative breast cancer Eur J Cancer 44 2799 2805
46. P Rolland I Spendlove Z Madjd EA Rakha P Patel IO Ellis L Durrant 2007 The p53 positive Bcl-2 negative phenotype is an independent marker of prognosis in breast cancer Int J Cancer 120 1311 1317